OAG
GMAB icon

Orbis Allan Gray’s Genmab GMAB Stock Holding History

Orbis Allan Gray’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312M Sell
11,368,161
-1,557,417
-12% -$41.4M 1.07% 32
2026
Q1 		$347M Sell
12,925,578
-1,492,884
-10% -$44.7M 1.46% 28
2025
Q4 		$444M Buy
14,418,462
+3,340,456
+30% +$104M 1.86% 19
2025
Q3 		$340M Buy
11,078,006
+3,157,606
+40% +$76.9M 1.46% 27
2025
Q2 		$164M Buy
7,920,400
+2,209,659
+39% +$45.4M 0.8% 36
2025
Q1 		$112M Buy
5,710,741
+2,895,179
+103% +$60.7M 0.64% 38
2024
Q4 		$58.8M Buy
2,815,562
+1,138,769
+68% +$25M 0.32% 50
2024
Q3 		$40.9M Buy
+1,676,793
New +$44.8M 0.22% 56

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Orbis Allan Gray's GMAB Position: Q2 2026 in Review

Orbis Allan Gray reduced its Genmab (GMAB) stake by 12% in Q2 2026, selling an estimated $41.4M and leaving 11,368,161 shares worth $312M. The position accounts for 1.07% of the portfolio, ranked #32.

Orbis Allan Gray first reported a position in GMAB in Q3 2024 and has held it in 8 quarters since. The position peaked at $444M in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Orbis Allan Gray held 11,368,161 shares of Genmab worth $312M as of Q2 2026.
  • Orbis Allan Gray sold 1,557,417 Genmab shares in Q2 2026, an estimated $41.4M.
  • Genmab made up 1.07% of Orbis Allan Gray's portfolio in Q2 2026, its #32 holding.
  • Orbis Allan Gray first reported a position in Genmab in Q3 2024 and has held it in 8 quarters since.
  • Orbis Allan Gray's Genmab position peaked at $444M in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Orbis Allan Gray's 13F filing for Q2 2026, filed 14 Aug 2026.